This report aims to provide detailed insights into the global Biomarkers Market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

Expected Revenue Growth:
The global biomarkers market size was valued at USD 43.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 12.6% from 2021 to 2026.
Growth in the biomarkers market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, increasing funds & grants for biomarker research, and continuous product innovations.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43

The infectious diseases segment accounted for the largest share of the disease indication segment in the biomarkers market in 2020.
Based on disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2020, the infectious diseases segment accounted for the largest share of the biomarkers market. The large share of this segment can be attributed to the growing prevalence of infectious diseases, coupled with the outbreak of the COVID-19 pandemic.

The efficacy biomarkers segment accounted for the largest share of the type segment in the biomarkers market in 2020.
Based on type, the biomarkers market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. In 2020, the efficacy biomarkers segment accounted for the largest share of the global biomarkers market. The large share of this segment can be attributed to the ability of these biomarkers to evaluate the therapeutic efficacy of drug products.

The Asia Pacific region is the fastest-growing region of the biomarkers market in 2020.
In 2020, the Asia Pacific region accounted for the fasted growing region of the biomarkers market. The growth of this segment is primarily due to the increasing use of biomarkers for diagnostic purposes, the growing prevalence of chronic diseases, favorable government initiatives, and the growing focus on genomic & proteomic research projects.

Some of the leading players operating in the biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).

By product & service segment, the consumables segment accounted for the largest share of the biomarkers market in 2020.
By product, the biomarkers market is segmented into consumables, services, and software. In 2020, the consumables segment accounted for the largest share of the global biomarkers market. The large share of this segment can primarily be attributed to the increasing use of kit-based products for biomarker testing and the repeated purchase of consumables.

By type, the efficacy biomarkers segment accounted for the largest share of the biomarkers market in 2020.
Based on type, the biomarkers market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. In 2020, the efficacy biomarkers segment accounted for the largest share of the global biomarkers market. The large share of this segment can be attributed to the ability of these biomarkers to evaluate the therapeutic efficacy of drug products.
By disease indication, infectious diseases segment accounted for the largest share of the biomarkers market in 2020.
Based on disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2020, the infectious diseases segment accounted for the largest share of the biomarkers market. The large share of this segment can be attributed to the growing prevalence of infectious diseases, coupled with the outbreak of the COVID-19 pandemic.

By application, the diagnostics application segment accounted for the largest share of the biomarkers market in 2020.
Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. The use of biomarkers for the diagnosis of multiple diseases, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders, is on the rise. The increasing use of biomarkers is a major factor that drives the growth of the diagnostics segment of the biomarkers market.

North America accounted for the largest share of the biomarkers market in 2020.
In 2020, North America accounted for the largest share of the market. The large share of this region can be attributed to the growing use of biomarkers in personalized medicine, various growth strategies adopted by key players with established pharmaceutical companies in this region, and a higher adoption rate of biomarkers for disease diagnostics, majorly in cancer diagnosis.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=43

Key Market Player
The biomarkers market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441